Is Zoltuximab/Veloximab covered by medical insurance?

Zolbetuximab (zolbetuximab)-Vyloy is a new monoclonal antibody drug that has attracted attention in the international oncology community in recent years. It mainly targets the CLDN18.2 protein and has shown high clinical application potential in some patients with gastric cancer and gastroesophageal junction cancer. As clinical research results are gradually released, more and more patients and doctors are beginning to pay attention to its accessibility.

Judging from the development trend, zotuximab has been approved for marketing in some countries, but the medical insurance systems in different regions have different evaluation mechanisms for the access of innovative drugs. Usually, a drug needs to go through a series of processes such as clinical value assessment, pharmacoeconomic analysis, and market price negotiation before it can be included in the medical insurance reimbursement catalog.

Therefore, in many countries, zotuximab is still in the new drug stage, and medical insurance coverage has not yet been fully implemented. For the Chinese market, since medical insurance negotiations need to take into account clinical needs, patient population size, drug pricing, and comparison with other treatments, whether it can quickly enter medical insurance in the short term still has a large impact on policy and economic factors.

However, it is worth noting that in recent years, the National Medical Insurance Administration’s negotiation efficiency for new anti-cancer drugs has continued to improve. Many international original drugs were included in medical insurance soon after they were launched, significantly reducing the financial burden on patients. If zotuximab continues to demonstrate definite value in subsequent clinical applications and meets the cost-effectiveness ratio required for medical insurance negotiations, it is still very likely that it will enter medical insurance in the future. Patients and family members can continue to pay attention to the updated information of the National Medical Insurance Directory, and at the same time, obtain the most authoritative policy interpretation through the hospital pharmaceutical department or official channels.

Overall, the current coverage of zotuximab in medical insurance varies by country and region. In China, it has not yet been clearly included in the medical insurance catalog. However, policy trends show that once its clinical application value is further confirmed, it is expected to make positive progress in future medical insurance access.

Reference materials:https://www.astellas.com/en/news/29401